Our results support the hypothesis that the PRR is involved in de novo triglyceride synthesis pathways in the liver and the progression of hepatic fibrogenesis in NASH, strengthening the relevance of the PRR as a potential therapeutic target for treatment of the NAFLD spectrum. Here, ATP6AP2 is linked to metabolic dysfunction-associated steatohepatitis.